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Introduction: The impact of chronic obstructive pulmonary disease 
(COPD) on the mortality of patients with lung cancer has not been 
studied extensively. The objective of this study is to compare the 
mortality and clinical characteristics of patients with non–small-cell 
lung cancer (NSCLC) according to the presence of COPD.
Methods: The medical records of 221 smokers diagnosed with 
NSCLC were reviewed. Eligible patients were dichotomized into the 
COPD group (n = 111) and the non-COPD group (n = 110). The 
overall survival and clinical characteristics were compared, and pre-
dictors of worse survival were analyzed using Cox proportional haz-
ards regression.
Results: COPD was present in 50.2% of all patients with NSCLC, 
and most of the patients (92.8%) with COPD were unaware of the 
disease before the diagnosis of lung cancer. Patients in the COPD 
group were older and had a lower body mass index, higher  pack-years 
smoking history, higher frequency of dyspnea, and higher incidence 
of previous malignancy. The overall survival of enrolled patients 
and propensity score-matched subjects was comparable between the 
two groups (log-rank test, p = 0.2 and 0.396, respectively). Old age, 
low body mass index, advanced disease stage (stages III and IV), 
non-squamous histology, Eastern Cooperative Oncology Group per-
formance status of greater than or equal to 2, weight loss, and coex-
istence of interstitial lung disease were independent risk factors for 
shorter survival.
Conclusion: COPD frequently and subliminally coexists with 
NSCLC. Although differences in clinical characteristic did exist, 
there was no impact of COPD on the mortality of patients with 
NSCLC with a positive smoking history in this study.
Key Words: Non–small-cell lung cancer, Chronic obstructive pul-
monary disease, Mortality
(J Thorac Oncol. 2014;9: 812–817)
Chronic obstructive pulmonary disease (COPD) and lung cancer are two leading causes of death worldwide, 
ranked fourth (3.0 deaths per million) and seventh (1.5 deaths 
per million), respectively, in 2011.1 Cigarette smoking is a 
well-established cause of both COPD and lung cancer. Even 
though not all smokers develop COPD or lung cancer, smok-
ing is a main contributor to the development of both diseases. 
Smoking causes COPD in a subgroup of patients, lung cancer 
in other patients, and both diseases in still others. COPD is a 
strong risk factor for the development of lung cancer, and the 
prevalence of COPD is estimated at 40% to 70% of patients 
with lung cancer.2,3 Young and Hopkins4 stated that the rela-
tionship between COPD and lung cancer is similar to that of 
obesity and type 2 diabetes. Chronic airway inflammation is 
a key feature in the pathogenesis of COPD and lung cancer. 
Patients who are unable to cope with chronic inflammation 
and subsequent DNA damage may develop COPD and/or 
lung cancer.5
The clinical features and survival of patients with 
lung cancer are thought to differ according to the presence 
of COPD, but the results do not often coincide. The over-
all survival in the COPD group was worse than that in the 
non-COPD group in a study by Sekine et al.,6 whereas Arca 
et al.7 reported that survival was longer in the COPD group. 
Meanwhile, Ueda et al.8 and Gullon et al.9 reported that COPD 
was not a prognostic factor in patients with non–small-cell 
lung cancer (NSCLC).Various factors, including age, sex, 
stage of disease, ethnicity, comorbidities, smoking status, and 
so on, may affect the outcomes of patients with lung cancer. 
The aim of the current study was to compare the mortality of 
patients with NSCLC between COPD and non-COPD groups 
and to identify prognostic factors for worse survival.
MATERIALS AND METHODS
Study Population
A total of 221 smokers, including current and former 
smokers, who were newly diagnosed with NSCLC histologi-
cally and/or cytologically from January 2005 to January 2006 
at Seoul National University Hospital, Seoul, South Korea 
were recruited in this study. Only adult patients aged above 
40 years were included. The exclusion criteria were (1) the 
inability to verify the smoking status or pulmonary function 
test results (n = 271), (2) coexistence of a malignant disease 
that affected survival (n = 2), (3) the presence of a severe 
structural lung disease that affected lung function, such as 
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bronchiectasis or tuberculosis-destroyed lung (n = 36), (4) 
lung cancer as an incidentally found ground-glass nod-
ule (n = 4), and (5) status as a never-smoker (n = 92). The 
Institutional Review Board of Seoul National University 
Hospital approved the current study (approval number IRB-
H-1204-093-407). Eligible patients were categorized into the 
COPD group (n = 111) and the non-COPD group (n = 110) 
according to their lung function. The diagnosis of COPD was 
made by spirometry when the post-bronchodilator forced 
expiratory volume in 1 second (FEV
1
)/forced vital capac-
ity ratio was less than 0.7, in accordance with the Global 
Initiative for Chronic Obstructive Lung Disease guidelines. 
The overall survival and clinical characteristics were com-
pared between these two groups, and prognostic factors were 
analyzed. Overall survival was again compared between the 
two groups after propensity score matching.
Data Collection
All data on subjects’ baseline demographics and clinical 
characteristics were collected from a review of the medical 
records. Information regarding age, sex, number of smok-
ing pack-years, pulmonary function, Eastern Cooperative 
Oncology Group (ECOG) performance status, tumor, node, 
metastasis cancer stage, histologic type, method of treatment, 
symptoms at presentation, comorbid diseases, and serum 
level of carcinoembryonic antigen was obtained. A current 
smoker was defined as a patient who continued smoking 
upon diagnosis or stopped smoking less than 1 month before 
the diagnosis of lung cancer and had smoked more than 100 
cigarettes during their lifetime. A former smoker was defined 
as a patient who had smoked at least 100 cigarettes in their 
lifetime and had stopped smoking at least 1 month before 
the diagnosis of lung cancer. Subjects were excluded if they 
had never smoked or had smoked fewer than 100 cigarettes 
in their entire lifetime. The ECOG performance status was 
dichotomized by a cutoff value of 2. The 7th American Joint 
Committee on Cancer tumor, node, metastasis classifica-
tion was used to stage the lung cancer. The histologic types 
were divided into squamous cell carcinoma, adenocarcinoma, 
NSCLC not otherwise specified, and others, which included 
large cell carcinoma, carcinoid tumor, signet ring carcinoma, 
and mucoepidermoid carcinoma. The methods of treatment 
included surgery, chemotherapy, radiation, chemoradiation, 
and best supportive care. We searched for the date of death by 
first reviewing the medical records, and if it could not be iden-
tified, data from the Korean Ministry of Public Administration 
and Security on October 26, 2012, were used. The median 
duration of follow-up was 84.0 months in survived patients, 
and the median survival time of censored patients was 11.8 
months. The date of death of 125 (56.6%) patients was iden-
tified by the medical records review and that of 96 (43.4%) 
patients was identified by the data from the Korean Ministry 
of Public Administration.
Statistical Analysis
Comparison of continuous variables between the COPD 
and non-COPD groups was performed by an unpaired t test. 
We used Pearson’s χ2 test to compare categorical variables. 
Kaplan-Meier survival curves were used to evaluate the 
survival of patients with lung cancer, and differences were 
assessed by the log-rank test. The follow-up time for survival 
analysis was defined as the time in months from diagnosis of 
lung cancer to the date of death or the date of the last outpa-
tient visit. The independent risk factors for shorter survival 
were analyzed using a Cox proportional hazards regression 
model after adjustment for confounding variables. Only sta-
tistically significant variables in the univariate analysis were 
entered into the multivariate analysis. Hazard ratios (HRs) 
and 95% confidence intervals were estimated. For all tests, 
p less than 0.05 was considered to indicate statistical sig-
nificance. Statistical analyses were performed using SPSS 
version 18.0 for Windows (SPSS Inc., Chicago, IL). A pro-
pensity score matching using Stata 12 (College Station, TX) 
was performed to reduce bias in patient selection. All clinical 
variables and potential confounders were included in the pro-
pensity score analysis.
RESULTS
Demographic and Clinical Characteristics
A total of 221 patients comprising 111 (50.2%) in the 
COPD group and 110 (49.8%) in the non-COPD group were 
enrolled in the analysis. Only eight (7.2%) of the 111 COPD 
patients recognized that they had a COPD. The median age of 
all patients was 65 years, and most (96.8%) were male. Patients 
with COPD were significantly older than those without COPD 
(mean age ± standard deviation, 67.3 ± 8.0 versus 62.1 ± 10.3 
years; p < 0.001). The body mass index (BMI) was lower and 
the number of smoking pack-years was significantly higher 
in the COPD group than in the non-COPD group. The mean 
FEV
1
 and predicted percent of FEV
1
 were 1.9 liters (73.3%) 
in the COPD group and 2.5 liters (91.3%) in the non-COPD 
group, respectively. The gender ratio, ECOG performance sta-
tus, and serum carcinoembryonic antigen level were compa-
rable in both groups. There were more patients with stage VI 
lung cancer (35.5% versus 28.8%; p = 0.768) and histologic 
evidence of adenocarcinoma (35.5% versus 27.0%; p = 0.510) 
in the non-COPD group than in the COPD group, which were 
not statistically significant (Table 1). Coughing (43.2% versus 
43.6%; p = 0.953) was the most frequent symptom at presen-
tation, followed by sputum (36.0% versus 26.4%; p = 0.121), 
in both groups. The presenting symptoms were similar, with 
the exception of the fact that dyspnea (24.3% versus 13.6%; 
p = 0.043) was significantly more common in the COPD 
group than in the non-COPD group (Table 2). Hypertension 
was the most common comorbid disease in both groups, and 
coexistence of malignant diseases other than lung cancer was 
significantly more common in the COPD group (Table 3).
Comparison of Survival Between 
COPD and Non-COPD Groups
A total of 162 of 221 enrolled patients died and 59 sur-
vived during the study period. The median survival time was 
15.15 months in the COPD group and 23.25 months in the 
non-COPD group (log-rank test, p = 0.2; Fig, 1).  Kaplan-Meier 
survival estimates at 12, 24, and 60 months were 57.7% versus 
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68.2%, 38.7% versus 48.2%, and 29.7% versus 32.7% in the 
two groups, respectively. A total of 176 patients, comprising 
88 in each group, were selected after propensity score analy-
sis. The median survival time of the propensity score-matched 
COPD group was 15.9 months and that of the propensity 
score-matched non-COPD group was 21.5 months; this dif-
ference was not significant (log-rank test, p = 0.396; Fig. 2).
Prognostic Factors for Survival 
in the Study Population
Univariate Cox proportional hazards regression analysis 
showed that old age, low BMI, advanced disease stage (stages 
III and IV), non-squamous cell histology, low FEV
1
 (% pre-
dicted), low forced vital capacity (% predicted), poor perfor-
mance status, presence of dyspnea, weight loss, neurologic 
symptoms, and the coexistence of interstitial lung disease 
(ILD) were predictors of short survival. After multivariate 
analysis, old age, low BMI, advanced disease stage (stages III 
and IV), non-squamous cell histology, ECOG greater than or 
equal to two, presence of weight loss, and the coexistence of 
TABLE 1.  Baseline Characteristics of the Study Patients With 
Non–Small-Cell Lung Cancer
COPD  
(n = 111)
Non-COPD 
(n = 110) p Value
Age, yr 67.3 ± 8.0 62.1 ± 10.3 <0.001
Male%/female% 97.3/2.7 96.4/3.6 0.692
BMI, kg/m2 21.9 ± 3.0 22.7 ± 3.4 0.048
Pack-years 42.2 ± 18.6 35.8 ± 17.2 0.009
FEV
1
/FVC, % 57.3 ± 8.9 76.6 ± 5.7 <0.001
FEV
1,
 L 1.9 ± 0.5 2.5 ± 0.7 <0.001
FEV
1
, % 73.3 ± 18.2 91.3 ± 18.1 <0.001
FVC, L 3.3 ± 0.7 3.3 ± 0.9 0.782
FVC, % 93.2 ± 60.3 84.2 ± 16.8 0.130
ECOG status 0.241
  0–1 103 (92.8) 106 (96.4)
  ≥2 8 (7.2) 4 (3.6)
Stage 0.768
  I 23 (20.7) 21(19.1)
  II 15 (13.5) 14 (12.7)
  III 41 (36.9) 36 (32.7)
  IV 32 (28.8) 39 (35.5)
Histology 0.510
  Adenocarcinoma 30 (27.0) 39 (35.5)
  Squamous cell 53 (47.7) 43 (39.1)
  NSCLC, NOS 21 (18.9) 22 (20.0)
  Others 7 (6.3) 6 (5.5)
Treatment 0.314
  Surgery 46 (41.4) 46 (41.8)
  Chemotherapy 34 (30.6) 44 (44.0)
  Chemoradiation 7 (6.3) 5 (4.5)
  Radiation 7 (6.3) 3 (2.7)
  BSC 12 (10.8) 11 (10.0)
  Unknown 5 (4.5) 1 (0.9)
Serum level of CEA, ng/ml 53.0 ± 404.2 49.7 ± 262.3 0.946
Values are presented as mean ± standard deviation or No. (%).
BMI, body mass index; FEV
1
, forced expiratory volume in 1 second; FVC, forced 
vital capacity; ECOG, Eastern Cooperative Oncology Group; NSCLC, non–small-
cell lung cancer; NOS, not otherwise specified; BSC, best supportive care; CEA, 
carcinoembryonic antigen; COPD, chronic obstructive pulmonary disease.
TABLE 2.  Presenting Symptoms of the Study Patients
COPD  
(n = 111)
Non-COPD 
(n = 110) p Value
Cough 48 (43.2) 48 (43.6) 0.953
Sputum 40 (36.0) 29 (26.4) 0.121
Dyspnea 27 (24.3) 15 (13.6) 0.043
Hemoptysis 27 (24.3) 16 (14.5) 0.066
Weight loss 8 (7.2) 9 (8.2) 0.786
Thoracic pain 13 (11.7) 12 (10.9) 0.851
Extra-thoracic pain 2 (1.8) 8 (7.3) 0.05
Hoarseness 3 (2.7) 5 (4.5) 0.463
Neurologic symptom 3 (2.7) 4 (3.6) 0.692
Others 2 (1.8) 2 (1.8) 0.993
Asymptomatic 26 (23.4) 28 (25.5) 0.725
Values are presented as No. (%).
COPD, chronic obstructive pulmonary disease.
TABLE 3.  Comorbid Diseases of the Study Patients
COPD  
(n = 111)
Non-COPD 
(n = 110) p Value
Hypertension 28 (25.2) 26 (23.6) 0.783
Diabetes 14 (12.6) 15 (13.6) 0.822
Cardiovascular diseases 8 (7.2) 8 (7.3) 0.985
Malignant disease 11 (9.9) 3 (2.7) 0.028
ILD 4 (3.6) 5 (4.5) 0.723
Others 8 (7.2) 6 (5.5) 0.593
No comorbidities 58 (52.3) 66 (60.0) 0.246
Values are presented as No. (%).
ILD, interstitial lung disease; COPD, chronic obstructive pulmonary disease.
FIGURE 1.  Overall survival of patients with non–small-cell 
lung cancer according to the presence of chronic obstructive 
pulmonary disease.
815Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 6, June 2014 Impact of COPD on Mortality of NSCLC Patients
ILD retained significance. Univariate and multivariate analy-
ses were carried out on all the 221 patients. The presence of 
COPD was not a significant risk factor for mortality in the uni-
variate (HR, 1.223; p = 0.201) and multivariate (HR, 1.021; 
p = 0.932) analyses (Table 4). The subgroup analysis includ-
ing 92 operative patients also showed that COPD was not a 
prognostic factor in the univariate and multivariate analyses 
(data are not shown).
DISCUSSION
The aim of the current study was to analyze the impact 
of COPD on the mortality of patients with NSCLC and 
the differences in clinical and demographic characteristics 
according to the presence of COPD. There was no impact of 
COPD on the mortality of patients with NSCLC, and COPD 
was not a prognostic factor for worse survival. Independent 
poor prognostic factors were old age, low BMI, advanced 
disease stage, non-squamous cell histology, ECOG greater 
than or equal to two, presence of weight loss, and the coex-
istence of ILD.
It is well established that cigarette smoking is the main 
cause of both COPD and lung cancer2–4,10–15 and that a consid-
erable number of patients with lung cancer have COPD as a 
comorbid disease at the time of diagnosis.7,16,17 Over half of 
patients with lung cancer had coexisting COPD in the current 
study. Mina et al.18 and Arca et al.7 reported prevalences of 
COPD diagnosed by spirometry at the time of diagnosis of 
lung cancer of 32.5% and 39.8%, respectively. Exclusion of 
never-smokers in this study was the cause of the higher preva-
lence of COPD. Patients with lung cancer without a smoking 
history were excluded to eliminate bias from cigarette smok-
ing as much as possible. Tumor biology is also thought to be 
different in never-smokers with lung cancer.19,20 An interest-
ing finding of this study is that only 7.2% of patients with 
COPD were aware of their disease. This result coincides 
with previous reports that 72% to 93% of COPD cases were 
not diagnosed.21,22 Considering that airway obstruction is 
an important risk factor for lung cancer development after 
FIGURE 2.  Overall survival of propensity score-matched 
patients with non–small-cell lung cancer according to the 
presence of chronic obstructive pulmonary disease.
TABLE 4.  Univariate and Multivariate Analyses of Prognostic Factors for Overall Higher Mortality
Univariate Analysis Multivariate Analysis
HR 95% CI p Value HR 95% CI p Value
Presence of COPD
  Non-COPD 1 1
  COPD 1.223 0.898–1.664 0.201 1.021 0.630–1.656 0.932
Age, yrs 1.043 1.025–1.061 <0.001 1.056 1.035–1.077 <0.001
BMI, kg/m2 0.930 0.885–0.978 0.005 0.942 0.893–0.993 0.027
Stage
  I 1 1
  II 1.751 0.859–3.595 0.123 1.843 0.892–3.807 0.099
  III 4.072 2.306–7.190 <0.001 4.484 2.508–8.017 <0.001
  VI 8.603 4.853–15.249 <0.001 8.244 4.482–15.165 <0.001
Squamous cell 0.675 0.492–0.928 0.015 0.617 0.434–0.879 0.008
FEV
1
, % 0.986 0.978–0.994 0.001 0.993 0.980–1.007 0.335
FVC, % 0.980 0.971–0.990 <0.001 0.994 0.980–1.009 0.443
ECOG status
  0–1 1 1
  ≥ 2 3.322 1.791–6.164 <0.001 2.636 1.271–5.467 0.009
Dyspnea 2.215 1.540–3.188 <0.001 0.727 0.451–1.172 0.191
Weight loss 1.919 1.127–3.270 0.016 2.251 1.263–4.013 0.006
Neurologic symptom 3.291 1.529–7.082 0.002 1.918 0.806–4.564 0.141
ILD 2.688 1.357–5.323 0.005 2.401 1.182–4.877 0.015
COPD, chronic obstructive pulmonary disease; HR, hazard ratio; CI, confidence interval; body mass index; FEV
1
, forced expiratory volume in 1 second; FVC, forced vital capacity; 
ECOG, Eastern Cooperative Oncology Group; ILD, interstitial lung disease; BMI, body mass index.
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adjustment for smoking exposure,16,23,24 early detection of 
COPD is crucial because it will lead to early detection and 
treatment of lung cancer. Sekine et al.25 suggested that never-
smokers older than 60 years and who have a respiratory 
symptom such as a chronic cough could be candidates for 
spirometry screening for COPD.
Because COPD is considered to be a main cause of 
mortality and morbidity worldwide,12 increasing number of 
studies are evaluating the outcomes of patients with lung 
cancer and coexisting COPD. The results of these studies are 
quite diverse because enrolled patients of each study were dif-
ferent. Sekine et al.26 reported two conflicting results regard-
ing the impact of COPD on survival of patients with lung 
cancer. There was no significant difference in survival in a 
report from 2002; otherwise, the survival of the COPD group 
was significantly worse than that of the non-COPD group in a 
report from 2007.6 Nakajima et al.27 reported worse survival 
of the COPD group, Mina et al.18 reported similar survival 
between the two groups, and Arca et al.7 reported better sur-
vival in the COPD group. Meanwhile, Ueda et al.8 reported 
that the degree of airway obstruction was not associated with 
the prognostic outcome. Several factors are thought to have 
affected the various results of the current and previous stud-
ies. Taking many studies into consideration, COPD tends 
to increase the mortality of patients with early stage lung 
cancer, especially surgically resected stage ІA lung cancer. 
If patients with lung cancer of all stages are included in the 
analysis, it is assumed that COPD is not a prognostic fac-
tor. Likewise, the presence of COPD did not affect the over-
all survival of patients with lung cancer in this study, which 
included patients with NSCLC of all stages.
Non-squamous cell histology was an independent neg-
ative prognostic factor in the current study. The reason for 
this result may be the significantly fewer patients with stage 
IV squamous cell lung cancer (22.9%) than with stage IV 
 non-squamous cell lung cancer (39.2%). ILD was another 
negative prognostic factor for survival of patients with 
NSCLC, and nine (4.1%) enrolled patients had coexisting 
ILD in this study. Previous studies reported that patients with 
both ILD and lung cancer had a shorter overall survival than 
did those without ILD and that ILD was a significant negative 
prognostic factor.28–30 Coexisting ILD in patients with lung 
cancer should be considered to be an important prognostic 
factor.
The limitations of this study include the following: (1) 
This was a retrospective observational study based on medi-
cal records. Thus, control of many kinds of bias was impos-
sible, even with use of statistical methods. (2) The number of 
enrolled patients was relatively small because a considerable 
number (n = 271) were excluded because of an unidentifiable 
smoking history or lung function. (3) We could not identify 
the causes of deaths; thus lung cancer- or COPD-specific 
mortality could not be analyzed. Nevertheless, this study has 
an advantage over previous ones with respect to the fact that 
the impact of smoking was minimized because of exclusion 
of never-smokers and because a propensity score matching 
method was used.
In conclusion, COPD and NSCLC are often coexistent 
diseases, but the impact of COPD on the mortality of patients 
with NSCLC was minimal in this study population. Further 
prospective studies with larger numbers of patients are needed 
to clarify the relationship between COPD and lung cancer.
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